These particular patents are said to be a critical component of the company’s strategic plan to maximize the value of this strong IP position and the recent clinical trial data to pursue a corporate partnership related to Lipid Sciences’s HDL selective delipidation.
Lewis Meyer, president and CEO of Lipid Sciences, said: “Our selective delipidation process ‘energizes’ a patient’s own HDL particles to pick up excess lipids from plaque in the arterial walls and transport those lipids to the liver to be processed and naturally excreted from the body. Our proprietary process has the potential to address a significant unmet clinical need in cardiovascular disease.”